A higher possibility of finding viruses that cause Covid-19 was linked to patients who had taken the antiviral drugs.

There was also a 65% relative reduction in COVID-related medical visits (95% CI 24.4-83.8) with nirmatrelvir-ritonavir versus ...

Onconova Therapeutics Inc ( (TRAW) ) has released its Q3 earnings. Here is a breakdown of the information Onconova Therapeutics Inc presented ...

Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the ...

Paxlovid significantly shortened the time to symptom relief (median, 13 vs 15 days; hazard ratio [HR], 1.27) and resolution (16 vs 19 days; HR, 1.20) through 28 days and cut the number of ...

Chatham-Kent health agencies urge the public to take advantage of the flu and COVID-19 vaccines and RSV (respiratory ...

Illinois health officials receive flu and COVID-19 vaccinations, emphasizing the importance of immunization before the ...

COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, ...

New research from Emory University reveals that nasal autoantibodies in COVID-19 patients may help predict disease severity, ...

COVID-19 presents a broad range of symptoms, varying in intensity from mild to severe and even life-threatening.

New research from Emory University is providing a more precise prediction of COVID-19 severity that can be found by looking ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President ...